Strados Labs, a medical technology company harnessing the power of smart sensors to aid in early detection and predictions of worsening diseases for enhanced patient care, announced today it was granted a CE Mark for the Company’s RESP™ Smart Sensor Platform for respiratory health.
Currently, there are no convenient or simple ways to capture abnormal patient lung sounds and patterns remotely. With this first-of-its-kind smart sensor platform, measuring and recording, lung sounds remotely across a diverse mix of healthcare settings (e.g., hospitals—in- and out-patient, clinical trials, research and nursing homes) is possible—enabling the identification of abnormal breathing patterns anywhere and at any given time.
“Being granted this CE Mark in less than a year from receiving our FDA Class II 510(k) clearance for our RESP Smart Sensor Platform is a significant achievement for Strados. Our large pharma clients have many trials underway or planned in Europe, and this allows us to work with our customers on global research projects and in international markets,” said co-founder and CEO Nick Delmonico. “I’m incredibly proud of our team and how hard they’ve worked to get us to this next significant milestone.”